文献速递临床微生物质量管理与危急值

金属β-内酰胺酶肠杆菌目细菌的氨曲南联合头孢他啶-阿维巴坦药敏试验:实验室自建方法比较

Comparison of laboratory-developed methods for aztreonam plus ceftazidime-avibactam antimicrobial susceptibility testing for metallo-beta-lactamase-producing Enterobacterales.
PubMed 文献 · J Clin Microbiol · 2026-05-22

结果显示仅肉汤纸片洗脱法分类一致率超过90%(CDC 92.2%,JHU 96.1%),纸片叠加法性能最低且变异大,提示实验室自建联合药敏试验需标准化。

要点

  • 肉汤纸片洗脱法分类一致率CDC 92.2%、JHU 96.1%,为唯一超过90%可接受性能的方法。
  • 纸片叠加法分类一致率CDC 51%-76.5%、JHU 31%-49%,性能最低且变异最大。
  • 梯度扩散条叠加法和条-纸片邻近法分类一致率分别为71.6%-86.3%和80%-89.2%,未达可接受标准。

核心结论

  • 在四种实验室自建表型方法中,肉汤纸片洗脱法是唯一分类一致率和重现性均超过90%的方法。
  • 纸片叠加法性能最低且在不同中心和纸片制造商间变异最大,部分方法易过判耐药。

研究设计与样本

  • 比较四种表型方法(肉汤纸片洗脱、纸片叠加、梯度扩散条叠加、条-纸片邻近法)与参考肉汤微量稀释法(rBMD)平行检测的性能。

主要发现

  • CDC和JHU的分类一致率分别为:肉汤纸片洗脱法92.2%和96.1%,纸片叠加法51%-76.5%和31%-49%,梯度扩散条叠加法71.6%-86.3%和83.3%-86.3%,条-纸片邻近法82.4%-87.3%和80%-89.2%。
  • 梯度扩散条叠加法的基本一致率JHU为46.1%-62.7%,CDC为54.9%-92.2%。
  • 两中心间重现性:rBMD 93.1%,肉汤纸片洗脱法92.2%,纸片叠加法47.1%-53.1%,梯度扩散条叠加法76.5%-80%,条-纸片邻近法87.3%-88.9%。

临床怎么用

  • 对于产金属β-内酰胺酶肠杆菌目细菌的氨曲南联合头孢他啶-阿维巴坦药敏试验,肉汤纸片洗脱法可作为实验室自建方法中较可靠的选择。
  • 纸片叠加法性能低且变异大,不宜用于临床报告;其他方法需进一步标准化后方可考虑。

局限性

  • 原文指出实验室自建联合药敏试验变异大,需进一步工作改善标准化和协调化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Metallo-beta-lactamase (MBL)-producing Enterobacterales are a global public health concern. Infections caused by these pathogens are often hard to treat, with few effective agents currently available. While aztreonam-avibactam only recently gained U.S. and European regulatory approval, laboratories have implemented laboratory-developed tests (LDTs) using existing aztreonam and ceftazidime-avibactam reagents. We sought to compare the performance of four phenotypic methods, up to three reagent manufacturers, and two media manufacturers. One hundred two MBL-producing Enterobacterales isolates were evaluated at two sites (Centers for Disease Control and Prevention [CDC] and Johns Hopkins University [JHU] School of Medicine). The performance of four methods was evaluated: broth disk elution (BDE), disk stacking (DS), gradient diffusion strip stacking (SS), and a strip-to-disk proximity (strip-disk) method, which were compared to reference broth microdilution (rBMD) tested in parallel. Respective category agreement for CDC and JHU was 92.2% and 96.1% for BDE, 51%-76.5% and 31%-49% for DS, 71.6%-86.3% and 83.3%-86.3% for SS, and 82.4%-87.3% and 80%-89.2% for the strip-disk method. The SS essential agreement ranged from 46.1% to 62.7% for JHU and 54.9% to 92.2% for CDC. Interlaboratory reproducibility was 93.1% for rBMD, 92.2% for BDE, 47.1%-53.1% for DS, 76.5%-80% for SS, and 87.3%-88.9% for strip-disk. BDE was the only method that exceeded acceptable performance of >90% accuracy and reproducibility. DS had the lowest and most variable performance between sites and among the different disk manufacturers used. LDTs for combination testing can be highly variable, and further work is needed to improve standardization and harmonization to achieve accurate and reliable results for clinical purposes. IMPORTANCE: Carbapenem-resistant Enterobacterales are classified as an urgent public health threat in the Centers for Disease Control and Prevention's 2019 Antibiotic Resistance Threats Report. Among the most concerning resistance mechanisms are carbapenemase enzymes encoded on mobile genetic elements, which can spread rapidly between bacteria. Of the various carbapenemases, metallo-beta-lactamases are particularly challenging, as they confer resistance to nearly all beta-lactams, and current treatment options remain limited. While aztreonam-avibactam has been U.S. Food and Drug Administration (FDA)-approved for treating certain infections with limited or no alternative treatment options, no FDA-cleared susceptibility test is yet available. In this context, laboratory-developed methods, such as combination testing of aztreonam and ceftazidime-avibactam, play a critical role in guiding therapy. Our study evaluates several of the more common laboratory-developed tests compared to reference broth microdilution and found that broth disk elution was the most accurate; in contrast, other methods had variable performance, some demonstrating limited reliability and being prone to overcalling resistance.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Bhatnagar AS, Harris H, Jacobs E, et al. Comparison of laboratory-developed methods for aztreonam plus ceftazidime-avibactam antimicrobial susceptibility testing for metallo-beta-lactamase-producing Enterobacterales. J Clin Microbiol. 2026. PMID: 42171586. doi:10.1128/jcm.01800-25

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。